BioSeek will continue with preclinical studies for optimization and pharmaceutical property improvements.

BioSeek exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals for further investigation in inflammatory conditions. BioSeek will work on optimization of these two peptides and will be responsible for further development programs in indications outside of Amylin’s core therapeutic focus.

The candidates are a result of an ongoing joint research collaboration between the two companies that began last year. Under the collaboration, BioSeek applied its BioMAP® human biology screening systems to evaluate the potential of 500 peptides in Amylin’s polypeptide hormone library, Phormol™, to treat a range of inflammatory conditions. The deal stated that BioSeek could select two candidates for its preclinical portfolio. Amylin will receive milestone payments and royalties.

“Exercising this license for two promising peptides from Amylin significantly expands our internal pipeline of drug candidates and demonstrates the broad utility of our BioMAP platform of predictive human biology screens to enhance and accelerate drug discovery,” comments Michael C. Venuti, Ph.D., CEO of BioSeek. “By generating predictive preclinical human data on the pharmacological properties of Amylin’s Phormol library, the BioMAP platform provided insight into the potential utility of the peptides across multiple therapeutic areas.”

BioMAP Systems are primary cell-based models of human disease biology, designed to replicate cell and pathway interactions as they are observed in vascular inflammation, cardiovascular and respiratory diseases, fibrosis, and related clinical indications.

Previous articleEurogentec to Help Delphi Genetics Market Its Antibiotic Resistance Gene-Free Manufacturing Technology
Next articleGenentech Grants Ex-U.S. Rights Covering a Mid-Stage Cancer Drug to Roche